LBA52 A randomized phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma

• DOI: 10.1016/j.annonc.2023.10.046
• Publication Date: 2023-10-20T13:21:30Z
• Authors: O. Straume; C. Schuster; S. Aziz; K. Davidsen; J. Karlsen; A.J. Rayford; M.I. Siraji; H. Løvendahl Sven...; L. Reisæter; B.T. Gjertsen; L. Akslen; J. Lorens
• Keywords: Trametinib; Dabrafenib; Interim analysis; Progression-free survival